Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I

8 Jan 2017

Abstract excerpt

Myotonic dystrophy type I (DM1) is a disabling multisystemic disease that predominantly affects skeletal muscle. It is caused by expanded CTG repeats in the 3'-UTR of the dystrophia myotonica protein kinase (DMPK) gene. RNA hairpins formed by elongated DMPK transcripts sequester RNA-binding proteins, leading to mis-splicing of numerous pre-mRNAs. Here, we have investigated whether DM1-associated muscle pathology...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Genetic Neurodegenerative Diseases
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28067669
DOI: 10.1172/jci89616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type IPMID 28067669Read ↗

Acute, next‐generation AMPK activation initiates a disease‐resistant gene expression program in dystrophic skeletal muscleSemantic proximity Read ↗

The hallmarks of myotonic dystrophy type 1 muscle dysfunctionSemantic proximity Read ↗

Direct AMPK Activation Confers Mutation-Independent Therapeutic Benefit in Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Metformin extends the lifespan of iMSUD mice by rescuing physiologic dysfunction and modulating mechanisms of mTORC1 activationSemantic proximity Read ↗

Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific mannerSemantic proximity Read ↗

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy.Semantic proximity Read ↗

AMPK is mitochondrial medicine for neuromuscular disordersSemantic proximity Read ↗

Leucyl-tRNA Synthetase Contributes to Muscle Weakness through Mammalian Target of Rapamycin Complex 1 Activation and Autophagy Suppression in a Mouse Model of Duchenne Muscular DystrophySemantic proximity Read ↗

The AMPK-related kinase SNARK regulates muscle mass and myocyte survivalSemantic proximity Read ↗

Sustained Activation of mTORC1 in Skeletal Muscle Inhibits Constitutive and Starvation-Induced Autophagy and Causes a Severe, Late-Onset MyopathySemantic proximity Read ↗

MicroRNA-Based Therapeutic Perspectives in Myotonic DystrophySemantic proximity Read ↗

Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.